

14. The use of an animal with inactivated Gas6 in experiments to control cancer in that animal.
15. The use of an animal with inactivated Gas6 as an *in vivo* model of apoptosis.
16. Use according to claim 11 where said animal is a mouse.
17. Use according to claim 12 where said animal is a mouse.
18. Use according to claim 13 where said animal is a mouse.
19. Use according to claim 14 where said animal is a mouse.
20. Use according to claim 15 where said animal is a mouse.
21. The use of a soluble Gas6 receptor and/or neutralising antibodies against Gas6 and/or neutralising antibodies against a Gas6 receptor and/or an antagonist of Gas6 function for the manufacture of a medicament in the prevention and/or treatment of a disorder or disease caused by endothelial activation.
22. The according to claim 21 wherein the Gas6 receptor is one of AXL, MER, RSE.
23. The use according to claim 21 in which the endothelial activation is caused by inflammation, apoptotic stimuli or production of toxic substances.
24. The use according to claim 21 in which the endothelial activation results in a cardiovascular disorder or disease.

25. The use according to claim 21 in which the endothelial activation results in one of atherothrombosis, venous thromboembolism, arterial thromboembolism, stroke, arterial stenosis, arterial restenosis, ischemic heart disease, myocardial infarction, diabetic microangiopathy, diabetic macroangiopathy and allograft arteriosclerosis.
26. The use according to claim 21 in which the endothelial activation results in excessive angiogenesis.
27. The use according to claim 26 in which the excessive angiogenesis contributes to chronic inflammatory disorders such as rheumatoid arthritis or non healing ulcerations.
28. The use according to claim 26 in which the excessive angiogenesis results to the progression of cancer.
29. The use of a soluble Gas6 receptor and/or neutralising antibodies against Gas6 and/or neutralising antibodies against a Gas6 receptor and/or an antagonist of Gas6 function for the manufacture of a medicament in the prevention and/or treatment of an individual with an elevated risk for a disorder or disease, the elevated risk being caused by endothelial dysfunction.
30. The use according claim 29 in which the endothelial dysfunction is caused by surgery.
31. The use according to claim 30 in which the dysfunctional results in a disorder or disease selected from one of systemic inflammation, multiple organ failure and diffuse intravascular coagulation.